Linked Life Data

20131224

Source:http://linkedlifedata.com/resource/pubmed/id/20131224

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2010-2-4
pubmed:abstractText
The increasing incidence of antibiotic resistance in human pathogens is of significant concern. Resistance to the widely-used and highly effective glycopeptide antibacterial agent vancomycin, which has been in clinical use for over half a century, has emerged in staphylococci and enterococci. This has spurred the development of newer glycopeptide agents, some of which show activity against vancomycin-resistant organisms. The newer agents currently being developed contain lipophilic side-chains, which distinguish them from vancomycin; as such, they are categorized as lipoglycopeptides. Oritavancin, telavancin, and dalbavancin are lipoglycopeptides in late-stage development to combat Gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci. This unit describes methods that may be used to assess the in vitro activities of lipoglycopeptides. The methods include susceptibility assays, time-kill and time-kill-synergy assays, inhibition of synthesis of macromolecules, membrane perturbation assays, and measurement of activity against biofilms.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
1934-8533
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
Chapter 17
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
Unit17.1
pubmed:meshHeading
pubmed:year
2010
pubmed:articleTitle
Characterization of the in vitro activity of novel lipoglycopeptide antibiotics.
pubmed:affiliation
The Medicines Company, Saint-Laurent, Quebec, Canada.
pubmed:publicationType
Journal Article